Valuation: AbbVie

Market Cap 470B 403B 378B 345B 652B 44,809B 654B 4,474B 1,736B 22,603B 1,763B 1,725B 74,794B P/E 2026 *
33.6x
P/E 2027 * 24.8x
Enterprise Value 530B 455B 427B 390B 736B 50,580B 738B 5,051B 1,959B 25,514B 1,991B 1,947B 84,427B EV / Sales 2026 *
7.84x
EV / Sales 2027 * 7.09x
Free-Float
95.71%
Yield 2026 *
2.61%
Yield 2027 * 2.74%
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-3.48% - - 470B
-3.59%-2.96%+71.06%+114.83% 1,100B
-1.15%-0.41%+51.34%+62.41% 658B
-1.09%+1.54%+26.67%+79.22% 470B
-1.47%+2.05%+41.71%+42.09% 372B
-0.90%+1.29%+25.62%+41.75% 304B
-1.94%+1.53%+3.05%+13.24% 264B
-0.43%+3.54%+52.65%+71.75% 239B
-0.93%+2.90%-16.98%-52.28% 213B
-0.46%+3.24%+29.73%+92.67% 184B
Average -1.26%+3.01%+31.65%+51.74% 422.54B
Weighted average by Cap. -1.10%+2.21%+42.86%+68.24%

Financials

2026 *2027 *
Net sales 67.58B 57.99B 54.4B 49.71B 93.77B 6,448B 94.1B 644B 250B 3,252B 254B 248B 10,762B 73.52B 63.09B 59.18B 54.08B 102B 7,014B 102B 700B 272B 3,538B 276B 270B 11,708B
Net income 13.86B 11.89B 11.16B 10.2B 19.23B 1,322B 19.3B 132B 51.23B 667B 52.04B 50.91B 2,207B 18.91B 16.23B 15.22B 13.91B 26.24B 1,804B 26.33B 180B 69.9B 910B 71.01B 69.46B 3,012B
Net Debt 60.49B 51.91B 48.69B 44.49B 83.92B 5,771B 84.22B 576B 224B 2,911B 227B 222B 9,633B 51.66B 44.33B 41.58B 38B 71.68B 4,929B 71.93B 492B 191B 2,486B 194B 190B 8,227B
Logo AbbVie
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA